Kuwedzera bhenefiti yebudiriro yemazuva ano yehutano hwevanhu neChikafu neDrug Administration's (FDA) mvumo yekutanga yemuromo antiviral kurapwa kweCCIDID-19 pamusika, eMed iri kugadzirira kusangana nechido ichocho. Iyo kambani inorumbidza iyo FDA nePfizer pane iyi nhanho yakakosha mukurwisa COVID-19.
Test-to-Treat ™, inosimudzira kune yazvino kumba, yakasimbiswa yekuyedza mhinduro, yakagadzirwa kuti ifambise kukurumidza kupihwa kwemishonga yekurapa antiviral kune vatengi vayo kana vakaedza kuti vane COVID-19. Iyo ichangobva kubvumidzwa antiviral therapeutic kubva kuPfizer inoshanda zvakanyanya kana yakatangwa nekukurumidza sezvinobvira mushure mekuongororwa kweCCIDID-19 uye mukati memazuva mashanu echiratidzo chatanga - chikuva chakagadzirirwa kuvhara mukaha pakati pekuongororwa uye kurapwa kubva mukunyaradza uye kuchengetedzeka kwechirwere. musha wevatengi. Nemadhora makumi maviri nemashanu emadhora, mutengi anogona kushanyira webhusaiti yekambani kuti atungamirirwe kuburikidza nehurongwa hwekuyedza kumba uye kugashira mhinduro dzakasimbiswa mumaminitsi gumi nemashanu izvo zvinogona kutungamira kunyoreswa kwemumuromo antiviral kana vakasangana nezvinodiwa.
Iyo kambani zvakare yakagadzirira kuzadzisa kupihwa kwehurumende kuyedza kwemahara nekupa mhinduro dzakasimbiswa. Izvi zvinoreva kuti vanhu vekuAmerica vanogona kuwana bvunzo dzemahara kubva kuhurumende uye kushandisa eMed kuwana mhinduro dzakasimbiswa dzinodiwa pakufamba, kubasa nezvimwe.
ZVOKUBVA MUNYAYA INO:
- For $25 dollars, a consumer can visit the company website to be guided through the at-home testing process and receive validated results in 15 minutes that can lead to prescription for the oral antiviral if they meet the required criteria.
- The newly-approved antiviral therapeutic from Pfizer is most effective when initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset — the platform is designed to close the gap between diagnosis and treatment from the comfort and safety of the consumer’s home.
- To maximize the benefit of today’s positive development for population health with the Food and Drug Administration’s (FDA) authorization of the first oral antiviral for treatment of COVID-19 in the market, eMed is preparing to meet that need.
